Evidence map›Paper›PMID 38605359›Full record

ArticleWorld journal of surgical oncology2024

Assessment of disease control rate and safety of sorafenib in targeted therapy for advanced liver cancer.

Daolin Zeng, Chunlin Yu, Shiyao Chen, Long Zou, Junjun Chen, Linlong Xu

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in World journal of surgical oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
1.5field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 4 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Article
  6. World journal of gastroenterology · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 1 country.

Daolin ZengMinimally Invasive Intervention Department, Ganzhou People's Hospital, Ganzhou, Jiangxi, 341000, China.
Chunlin YuMinimally Invasive Intervention Department, Ganzhou People's Hospital, Ganzhou, Jiangxi, 341000, China.
Shiyao ChenJiangxi Institute of Applied Science and Technology, Nanchang, Jiangxi, 330012, China.
Long ZouHepatobiliary Surgery Department, Jiangxi Province Cancer Hospital, Nanchang, Jiangxi, 330029, China.
Junjun ChenKey Laboratory of Personalized Diagnosis and Treatment of Nasopharyngeal Carcinoma, National Health Commission (NHC), Jiangxi Cancer Hospital of Nanchang Medical College, Nanchang, Jiangxi, 330029, China.
Linlong XuDepartment of Hepato-Biliary-Pancreatic Surgery, Jiujiang First People's Hospital, 48 Taling South Road Jiujiang, Jiujiang, Jiangxi, 332000, China. xulinlong0917@163.com.
Ganzhou People's Hospital · CNJiangxi Provincial Cancer Hospital · CNInstitute of Applied Technology · CNJiujiang First People's Hospital · CN

Funding

Jiangxi Province Traditional Chinese Medicine Science and Technology Plan Project 2020B0349Natural Science Foundation of Jiangxi Province 20212BAB216064
6 · The paper itself

Abstract

objectiveThe clinical efficacy and safety of sorafenib in patients with advanced liver cancer (ALC) were evaluated based on transarterial chemoembolization (TACE).

methods92 patients with ALC admitted to our hospital from May 2020 to August 2022 were randomly rolled into a control (Ctrl) group and an observation (Obs) group, with 46 patients in each. Patients in the Ctrl group received TACE treatment, while those in the Obs group received sorafenib molecular targeted therapy (SMTT) on the basis of the treatment strategy in the Ctrl group (400 mg/dose, twice daily, followed by a 4-week follow-up observation). Clinical efficacy, disease control rate (DCR), survival time (ST), immune indicators (CD3+, CD4+, CD4+/CD8+), and adverse reactions (ARs) (including mild fatigue, liver pain, hand-foot syndrome (HFS), diarrhea, and fever) were compared for patients in different groups after different treatments.

resultsthe DCR in the Obs group (90%) was greatly higher to that in the Ctrl group (78%), showing an obvious difference (P < 0.05). The median ST in the Obs group was obviously longer and the median disease progression time (DPT) was shorter, exhibiting great differences with those in the Ctrl group (P < 0.05). Moreover, no great difference was observed in laboratory indicators between patients in various groups (P > 0.05). After treatment, the Obs group exhibited better levels in all indicators. Furthermore, the incidence of ARs in the Obs group was lower and exhibited a sharp difference with that in the Ctrl group (P < 0.05).

conclusionSMTT had demonstrated good efficacy in patients with ALC, improving the DCR, enhancing the immune response of the body, and reducing the incidence of ARs, thereby promoting the disease outcome. Therefore, it was a treatment method worthy of promotion and application.

Indexed as

Antineoplastic AgentsCarcinoma, HepatocellularChemoembolization, TherapeuticLiver NeoplasmsCombined Modality TherapyHumansNiacinamidePhenylurea CompoundsSorafenibTreatment OutcomeAntineoplastic AgentsNiacinamidePhenylurea CompoundsSorafenibAdvanced liver cancerClinical efficacyDisease control rateSorafenibTargeted therapyTransarterial chemoembolization

Identifiers

PMID38605359
PMCPMC11010384
OpenAlexW4394759789

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.